Davita Clinical Research
Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease
  • Home >
  • About Us >
    • Leadership >
    • Careers >
      • Our Culture >
      • Diversity & Belonging >
    • Our History >
    • Awards and Recognition >
  • Services >
    • Late Phase Renal Research (ESKD) >
    • Alliance Site Network >
    • International Trials >
  • News >
    • Press Releases >
    • Events >
  • Resources >
    • Blog >
    • Video Library >
  • Contact Us >
    • For Sponsors >
    • For Investigators >
    • For Participants >
  • Home
  • About Us
    • Leadership
    • Careers
      • Our Culture
      • Diversity & Belonging
    • Our History
    • Awards and Recognition
  • Services
    • Late Phase Renal Research (ESKD)
    • Alliance Site Network
    • International Trials
  • News
    • Press Releases
    • Events
  • Resources
    • Blog
    • Video Library
  • Contact Us
    • For Sponsors
    • For Investigators
    • For Participants
  • Search this site

  • Home
  • Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease

Posted by:

Courtney R, Sansone A, Smith W, Marbury T, Statkevich P, Martinho M, et al.  J Clin Pharmacol. 2005;45(2):185-192. Read more

Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction

Posted by:

Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, et al.  J Clin Pharmacol. 2005;45(10):1145-1152. Read more

An anti-inflammatory and antioxidant nutritional supplement for hypoalbuminemic hemodialysis patients: a pilot/feasibility study.

Posted by:

Kalantar-Zadeh K, Braglia A, Chow J, Kwon O, Kuwae N, Colman S, Cockram DB, Kopple JD. J Ren Nutr 2005;15:318-331 Read more

A matched comparison of serum lipids between hemodialysis patients and nondialysis morbid controls

Posted by:

Kalantar-Zadeh K, Kilpatrick RD, Kopple JD, Stringer WW.  Hemodial Int. 2005;9(3):314-24. Read more

Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction

Posted by:

Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, McAllister CJ, Alcorn H, Jr., Kopple JD, Greenland S.  Nephrol Dial Transplant 2005;20:1880-1888. Read more

Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study

Posted by:

Kalantar-Zadeh K, McAllister CJ, Miller LG. Nephrol Dial Transplant. 2005;20:1662-1669. Read more

Diagnostic discordance for hepatitis C virus infection in hemodialysis patients.

Posted by:

Kalantar-Zadeh K, Miller LG, Daar ES. Am J Kidney Dis. 2005;46(2):290-300. Read more

Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population

Posted by:

Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, McAllister CJ, Shinaberger CS, Gjertson DW, Greenland S. Am J Kidney Dis. 2005;46:489-500. Read more

Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions

Posted by:

Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Greenland S, Kopple JD.  Hypertension. 2005;45:811-817. Read more

A low lymphocyte percentage is a predictor of mortality and hospitalization in hemodialysis patients.

Posted by:

Kuwae N, Kopple JD, Kalantar-Zadeh K.  Clin Nephrol. 2005;63(1):22-34. Read more

Categories

  • Blog
  • Events
  • Press Releases
  • Video

Blog: A Guide to Different Models of SMOs

Navigate
  • Home
  • About Us
  • Services
  • News
  • Resources
  • Contact Us
Headquarters
DaVita Clinical Research®
6600 France Ave S Suite 660
Edina, MN 55435 (Map)
  • Telephone: 888-345-2567
  • Fax: 866-852-3241
Corporate
  • Careers
  • davita.com
  • mykidneyresearch.com
  • Renal Research FAQ
Follow us on:
  • LinkedIn
  • Twitter
  • YouTube
  • Facebook
  • © 2026 DaVita Inc.
  • Web privacy policy
  • Sitemap
  • Terms of use
x
x

View PDF